CD4 and graft versus host disease: The goal of the study was to determine a DLI dose that would result in a CD4+ cell count > 100/μL at Day +120 in ≥ 66% of patients with ≤ 33% grade II-III, ≤ 17% grade III, and no grade IV acute GvHD by Day +180.